Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.

Semin Oncol. 1999 Oct;26(5 Suppl 14):66-73. Review.

PMID:
10561020
2.

Rituximab: an insider's historical perspective.

Grillo-López AJ.

Semin Oncol. 2000 Dec;27(6 Suppl 12):9-16.

PMID:
11226006
3.

Rituximab: ongoing and future clinical development.

Grillo-López AJ, Hedrick E, Rashford M, Benyunes M.

Semin Oncol. 2002 Feb;29(1 Suppl 2):105-12. Review.

PMID:
11842397
4.

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F.

Blood. 1998 Sep 15;92(6):1927-32.

5.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R.

Blood. 1997 Sep 15;90(6):2188-95.

6.

Use of rituximab, the new FDA-approved antibody.

Leget GA, Czuczman MS.

Curr Opin Oncol. 1998 Nov;10(6):548-51. Review.

PMID:
9818234
7.
8.

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Hainsworth JD.

Semin Oncol. 2003 Feb;30(1 Suppl 2):9-15. Review.

PMID:
12652459
9.

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.

Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Review.

PMID:
11842390
10.

Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.

Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dubé I, Hewitt K, Berinstein NL.

Semin Oncol. 1999 Oct;26(5 Suppl 14):115-22.

PMID:
10561026
12.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
13.

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, Rosenberg J.

Curr Pharm Biotechnol. 2000 Jul;1(1):1-9. Review.

PMID:
11467356
14.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
15.

Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.

Kunkel L, Wong A, Maneatis T, Nickas J, Brown T, Grillo-López A, Benyunes M, Grobman B, Dillman RO.

Semin Oncol. 2000 Dec;27(6 Suppl 12):53-61. Review.

PMID:
11226001
16.

Radiolabeled antibody therapy of B-cell lymphomas.

Press OW.

Semin Oncol. 1999 Oct;26(5 Suppl 14):58-65. Review.

PMID:
10561019
17.

Preclinical and phase I and II trials of rituximab.

Maloney DG.

Semin Oncol. 1999 Oct;26(5 Suppl 14):74-8. Review.

PMID:
10561021
18.

Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.

Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock CS.

Cancer J. 2002 Sep-Oct;8(5):371-6.

PMID:
12416894
19.

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.

Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ.

Eur J Nucl Med. 2000 Jul;27(7):766-77.

PMID:
10952488
20.

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.

Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, Trümper L, Brugger W, Ostermann H, Atzpodien J, Hallek M, Aulitzky E, Hiddemann W.

Ann Hematol. 2000 Sep;79(9):493-500.

PMID:
11043420

Supplemental Content

Support Center